Compare Coursera Inc (COUR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Summit Therapeutics Inc — how do they compare? Coursera Inc trades at $5.58 (market cap $1.50B), while Summit Therapeutics Inc trades at $15.21 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 8× Coursera Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | SMMT | |
|---|---|---|
Market Cap | $1.50B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $26.98 |
52-Week Low | $5.09 | $12.55 |
Enterprise Value | $759.54M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.525, down 4.08% today, with a bearish technical signal from moving averages. Revenue grew to $757.5M in 2025, but net losses persist at -$51M. Recent Q2 2026 earnings beat expectations at $0.17 EPS, and the company made a $100M strategic investment in AI education firm LearnVector (Business Wire, July 28, 2026).
The stock offers upside to the $7.70 consensus price target, supported by a majority buy rating from analysts. However, profitability challenges and competitive pressures in online education pose risks. Positive cash flow trends and institutional interest provide a foundation for recovery if execution improves.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
